Publications by authors named "Fang-Hua Xu"
Article Synopsis
- Heart failure (HF) is a serious global health issue, often accompanied by anemia, which can affect patient outcomes; SGLT2 inhibitors like dapagliflozin are known to improve cardiovascular outcomes in HF patients.
- The purpose of the ADIDAS trial is to determine if correcting anemia is necessary for the positive effects of dapagliflozin in HF patients, through a double-blind study involving up to 2030 participants over 12 months.
- The main focus is on hospital admissions and all-cause deaths, with secondary measures including quality of life scores, walking ability, and hemoglobin levels, aiming to uncover any links between hemoglobin changes and patient outcomes.
Benign prostatic hyperplasia (BPH) is the most common benign disease of the prostate gland and is caused by benign hyperplasia of the smooth muscle cells and stromal cells in this important gland. BPH is also the most common disease underlying lower urinary tract symptoms (LUTS). The incidence of BPH increases with age and affects more than half of all men 50 years or older.
View Article and Find Full Text PDFObjective To investigate the expression and clinical significance of late endosomal/lysosomal adaptor,mitogen-activated protein kinase and mammalian target of rapamycin activator 3(LAMTOR3)in bladder carcinoma.Methods Oncomine and Expression Atlas were used to extract the useful mining gene chip database for analyzing the expression of LAMTOR3 in bladder carcinoma tissues and cell lines,and the correlation of LAMTOR3 with the clinicopathological features were analyzed.RT-PCR,Western blot,and immunohistochemistry were performed to detect the expression of LAMTOR3 in bladder carcinoma cell lines,specimens,and adjacent normal tissues for verifying the results exploited from the above databases.
View Article and Find Full Text PDFObjectives: The human beta(1)-adrenergic receptor, an important therapeutic target in cardiovascular diseases, has 2 common functional polymorphisms (Ser49Gly and Gly389Arg). Our study aimed to confirm that beta(1)-adrenergic receptor polymorphisms affect the blood pressure response to metoprolol monotherapy in the Chinese population with hypertension.
Methods: beta(1)-Adrenergic receptor genotype was determined by polymerase chain reaction-restriction fragment length polymorphism assay for 223 patients with essential hypertension.